EUCTR2019-002514-40-IT进行中（未招募）1 期
Phase II study on the safety and efficacy of cysteamine in association with standard tuberculosis therapy for the treatment of patients with pulmonary tuberculosis: a new therapy for tuberculosis directed at the host - CISTA-TB
ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI0 个研究点目标入组 30 人开始时间: 2021年5月24日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age between 18 and 65;
- •Clinical signs and symptoms of pulmonary tuberculosis (new diagnosis)
- •Abnormal chest x-ray compatible with pulmonary tuberculosis
- •At least one positive sputum for acid-resistant bacteria (BAAR) (bacterisoscopic examen) [and molecular confirmation for M. tuberculosis by Xpert Mycobacterium tuberculosis (MTB) / rifampicin resistance (RIF) with a cycle threshold (Ct) <28.
- •Sensitivity to antituberculosis drugs by phenotypic pharmacosensitivity test on MGIT liquid medium
- •Weight =>50 kg
- •Karnofsky score of at least 60
- •Levels of leukocyte cystine (<2 nmol hemicystine / mg protein)
- •Ability to provide informed consent
- •Ability to adhere to control visits
- •Consent to be hospitalized for 4 weeks
- •Consent to perform a treatment under direct observation
- •Consent to comply with the following contraception requirements for people of childbearing age starting 2 weeks before enrollment at 18 weeks after the drug was administered:
- •- Vasectomy with documented azoospermia for male subjects
- •- Use of the condom for male subjects or one of the following contraceptive methods by the partner: Combined hormonal contraceptives associated with ovulation inhibitors (oral, intravaginal, transdermal), Progestinal hormonal contraceptives associated with an ovulation inhibitor (oral, injectable, implantable), Intrauterine devices, Intrauterine devices with hormonal release system, Bilateral tubal binding, Partner's vasectomy,
- •- Sexual abstinence;
- •The infertility condition in female subjects will be defined:
- •- In the pre-menopausal phase with: documented tubal closure; documented hysteroscopic tubal occlusion procedure, hysterectomy, documented ovariectomy
- •- Post-menopausal phase: with 12 months of spontaneous amenorrhea and confirmation by hormonal dosage
- •Consent to carry out a pregnancy test before the administration of the experimental drug for female subjects of childbearing age
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Age> 65 years and <18 years
- •Use of antiretroviral drugs
- •Hemoglobin concentration under 10 g / dl
- •Elevation of creatinine kinase at baseline more than three times the upper limit of normal
- •Abnormal baseline laboratory values ¿¿(baseline concentration of alanine aminotransferase (ALT) more than three times the upper limit of normal, serum creatinine concentration more than twice the upper limit of normal, total bilirubin serum level greater than twice the upper limit of normal, platelet count <100,000 / mm3, white blood cells (WBC) <2500 (mcL)
- •Pregnancy or breast-feeding
- •Silico-Tuberculosis
- •Previous anti-tuberculosis treatment or use for more than 5 days of anti-tuberculosis drugs in the 3 months prior to enrollment
- •Concomitant diseases or conditions for which anti-tuberculosis drugs are contraindicated. These include severe liver failure, acute arthritis, peripheral neuropathy
- •Presence of any physical or psychological condition which, according to the person responsible of the study, makes participation in the study inadvisable
- •Infection with an isolate known to be resistant to a first drug for tuberculosis, for example rifampicin
- •Scheduled or current use of cyclosporine, tacrolimus, erythromycin or colchicine
- •TB with extra-pulmonary localization
- •Therapy with immunosuppressive drugs and / or NSAIDs and / or cortisone drugs
- •TB resistant to first and second line drugs
- •Inability to understand and sign informed consent
- •Positivity for HIV, HCV, HBV (HBsAg positivity)
- •Hepatic impairment (Child A-C), Renal failure (creatinine clearance <50 ml / min), heart failure (NYHA III-IV), decompensated diabetes mellitus, neoplasms, ongoing neurological / psychiatric pathology (eg depression, psychotic crisis, suicide attempt), inflammatory bowel diseases or gastric ulcer / duodenal treatment, autoimmune diseases
- •Abuse of drugs / alcohol
- •Hypersensitivity to cysteamine or penicillin
- •Current use of cysteamine
- •Participation in other Clinical Trials
研究者
相似试验
已完成
不适用
Clinical study on the safety and usefulness of Cyclodextrin inclusion welding Tretinoin for wrinkles and pigmentation of the skiJPRN-UMIN000010597Tohoku University Graduate School of Medicine60
已完成
2 期
A study for evaluating efficacy of cystine and theanine against peripheral neuropathy of oxaliplatin as a supportive treatmentPeripheral neuropathyJPRN-UMIN000020456Sendai City Medical Center, Sendai Open Hospital40
招募中
1 期
Safety and efficacy of potentised forms of cisplatin and docetaxelCTRI/2020/05/025045Central Council for Research in Homoeopathy
进行中（未招募）
不适用
A study to find out whether treating patients who have liver metastases from eye melanoma with radiofrequency ablation combined with ipilimumab, will kill the tumor without them having too many adverse events.EUCTR2011-004200-38-NLKI-AV
已完成
不适用
Phase II study evaluating efficacy and safety of peripheral blood stem cell harvest with bortezomib for multiple myelomaMultiple MyelomaJPRN-UMIN000010258Fourth Department of Internal Medicine, Sapporo Medical University, School of Medicine30